NASDAQ:SNGX - Soligenix Stock Price, Forecast & News

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Soligenix, Inc. (NASDAQ:SNGX) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $1.30 million during the quarter, compared to analyst estimates of $1.40 million. Soligenix had a negative net margin of 193.39% and a negative return on equity of 212.69%. View Soligenix's Earnings History.

Soligenix is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Soligenix.

1 brokers have issued 12 month price objectives for Soligenix's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Soligenix's share price to reach $4.00 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Soligenix.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soligenix.

Media coverage about SNGX stock has been trending negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Soligenix earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Soligenix.

Soligenix saw a drop in short interest in January. As of January 31st, there was short interest totalling 127,300 shares, a drop of 19.4% from the January 15th total of 157,900 shares. Based on an average daily trading volume, of 251,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.7% of the shares of the company are short sold. View Soligenix's Current Options Chain.

Some companies that are related to Soligenix include LifeVantage (LFVN), Theratechnologies (THERF), Arcturus Therapeutics (ARCT), Arbutus Biopharma (ABUS), Theratechnologies (THTX), Cerecor (CERC), Affimed (AFMD), Fortress Biotech (FBIO), Nature's Sunshine Products (NATR), Athersys (ATHX), Chiasma (CHMA), TAIWAN LIPOSOME/S (TLC), GlycoMimetics (GLYC), Strongbridge Biopharma (SBBP) and Kezar Life Sciences (KZR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Verastem (VSTM), Onconova Therapeutics (ONTX), Sunesis Pharmaceuticals (SNSS), T2 Biosystems (TTOO), Energy Transfer LP Unit (ET), Nokia Oyj (NOK) and Biocept (BIOC).

Soligenix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.51%). Company insiders that own Soligenix stock include Christopher J Schaber, Diane L Parks, Jerome B Zeldis and Mark E Pearson. View Institutional Ownership Trends for Soligenix.

SNGX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Diane L Parks, Jerome B Zeldis and Mark E Pearson. View Insider Buying and Selling for Soligenix.

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNGX stock can currently be purchased for approximately $3.30.

Soligenix has a market capitalization of $68.15 million and generates $5.24 million in revenue each year. The biopharmaceutical company earns $-8,900,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Soligenix employs 14 workers across the globe.View Additional Information About Soligenix.

The official website for Soligenix is http://www.soligenix.com/.

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]